CM
Therapeutic Areas
Monopar Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Validive (clonidine HCl MBT) | Prevention of severe oral mucositis in head and neck cancer patients receiving chemoradiotherapy | Phase 2b/3 |
| MNPR-101 | Advanced cancers (e.g., pancreatic, triple-negative breast cancer) | Preclinical |
| MNPR-202 (camsirubicin) | Advanced soft tissue sarcoma | Phase 1b |
Leadership Team at Monopar Therapeutics
CD
Chandler D. Robinson, MD
Chief Executive Officer, Co-Founder, and Director
AP
Andrew P. Mazar, PhD
Chief Scientific Officer, Co-Founder, and Director
KR
Kim R. Tsuchimoto, CPA, CMA
Chief Financial Officer and Corporate Secretary
MJ
Michael J. Brown, JD
Chairman of the Board
AJ
Arthur J. Klausner, JD
Director
RW
Raymond W. Anderson
Director